Overview

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease

Status:
Completed

Trial end date:
2020-04-30

Target enrollment:

Participant gender:

Summary

Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients. Especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.

Phase:

Phase 3

Details

Lead Sponsor:

GWT-TUD GmbH

Treatments:

Anti-Inflammatory Agents
Aspirin
Rivaroxaban